ST LOUIS, MO – PierianDx, the forerunner in clinical genomic informatics, announced today that Molecular Diagnostics Laboratories (MDL) has standardized on its leading bioinformatics software platform in order to rapidly launch its BRCA1/2 genomic testing program.
MDL, based in Covington, KY, will utilize the PierianDx Clinical Genomicist Workstation™ 3.0 to jump-start its BRCA testing program. Branded BRCAware™, the program will operate in all 50 states through MDL’s distribution channel.
“We have partnered with PierianDx because of their extraordinary expertise and ability to quickly ramp up our next generation sequencing testing,” said Brad Denham, President of MDL. “Partnering with PierianDx will greatly expedite our entry into BRCA testing while saving us significant resources.”
MDL also selected PierianDx’s CGW because of its extensive collaborative knowledgebase of thousands of prior medical interpretations appropriately linked to patient-specific variants for both constitutional disorders and somatic cancer. This will allow MDL to build a future roadmap of assays for genomic testing, Denham said.
PierianDx CEO Ted Briscoe welcomed MDL into the growing community of commercial labs who are partnering with PierianDx.
“PierianDx is committed to providing our partners with the fastest path to personalized medicine,” said Briscoe. “We embrace MDL as the newest commercial lab to embrace our CGW platform and services.”
The PierianDx CGW 3.0 platform is a comprehensive, cloud-based software platform that provides clinical labs a customized on-ramp to Next Generation Sequencing (NGS). CGW is a turnkey solution that manages data and workflow for variant analysis and classification, medical interpretation and reporting. The CGW platform includes:
Integrated Platform – Seamlessly manages data and workflow for each patient case, flowing directly into the patient’s electronic medical record.
Flexible Engagement Model – Provides a modular engagement model that delivers unparalleled support for every stage of a client’s personalized medicine initiative.
Collaborative Knowledgebase – The PDx Collaborative Knowledgebase™ provides access to thousands of prior clinical interpretations, providing credible, peer-sourced insights.
Real-time Content – Offers breadth and depth of industry-leading content that is timely and extensively curated for accuracy and relevancy.
PierianDx enables clinical labs to deliver patient-specific diagnosis and treatments based on an individual’s DNA. In use since 2011, and regularly enhanced with new patient, clinical and research data, PierianDx’s proprietary Clinical Genomicist Workstation 3.0 software provides clinical labs everything they need to manage their next-generation sequencing processes. For more information, please visit www.pieriandx.com or @PierianDx on Twitter.